These are complex diseases that sit at the intersection of imaging, genetics, electrophysiology, heart failure, and increasingly clinical pharmacology. Your expertise spans echocardiography, cardiac CT, and CMR at a time when cardiovascular imaging is becoming increasingly subspecialised. Can you share an example where integrating several imaging techniques fundamentally changed a diagnosis, risk assessment, or management strategy? As a member of the European Association of Cardiovascular Imaging (EACVI) Scientific Committee, you have an unusual vantage point on developments across European cardiovascular imaging. HCM is one of the few areas in cardiology where we’ve seen simultaneous advances in imaging, risk prediction, and disease-specific therapy.